Kashipathi Manjunath Poornima
About Kashipathi Manjunath Poornima
Data last updated:
Kashipathi Manjunath Poornima has 10 years in corporate governance. Holds Director role. Currently with 1 company, including Deshpande Drugs Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Deshpande Drugs Private Limited at ₹9.62 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Deshpande Drugs Private Limited U51103KA2015PTC083096 | Director | 09 Jun 2016 | 2015 | ₹9.62 Cr (FY 2025) | Active |
Previous companies
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Kashipathi Manjunath Poornima
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kashipathi Manjunath Poornima
Kashipathi Manjunath Poornima has 10 years in corporate governance. Holds Director role. Currently with 1 company, including Deshpande Drugs Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Deshpande Drugs Private Limited at ₹9.62 Cr (FY 2025).
Kashipathi Manjunath Poornima is associated with 1 company as Director, including Deshpande Drugs Private Limited (₹9.62 Cr).
Kashipathi Manjunath Poornima has expertise in General Business.
Kashipathi Manjunath Poornima has 10 years in corporate governance.
By reported revenue, the largest current company of Kashipathi Manjunath Poornima is Deshpande Drugs Private Limited, with revenue of ₹9.62 Cr (FY 2025).
Kashipathi Manjunath Poornima currently holds positions at 1 company: Deshpande Drugs Private Limited (₹9.62 Cr).